Creator: Help Dementia Editorial Team
Published: 2026-04-26T00:05:52

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Researchers find sits at the center of this dementia and brain health question.

A landmark study published in March 2025 has uncovered a surprising connection between the shingles vaccine and reduced dementia risk, suggesting that protecting yourself against the painful herpes zoster virus may also protect your brain. Researchers analyzing data from Wales’s vaccination program found that older adults who received the shingles vaccine were 20% less likely to develop dementia over seven years compared to unvaccinated individuals—a finding that has major implications for brain health and prevention strategies. For someone like Margaret, a 68-year-old who got vaccinated before experiencing her first shingles outbreak, the news carries dual reassurance: she avoided painful blistering lesions and may have also significantly reduced her likelihood of cognitive decline decades down the line.

The research goes even further. Among adults aged 65 and older who received two doses of the newer recombinant zoster vaccine, the dementia risk reduction jumped to 51%—a nearly dramatic difference that has caught the attention of neurologists, gerontologists, and public health officials worldwide. Even more remarkably, for those who already have dementia, the vaccine appeared to slow the disease’s progression, reducing the risk of dying from the condition by nearly 30 percentage points over nine years. This isn’t just about prevention anymore; it’s about changing the trajectory of one of the most feared diseases of aging.

How Can a Vaccine Against Shingles Lower Alzheimer’s and Dementia Risk?
The Real Impact on Dementia Progression and Mortality
Cardiovascular and Broader Health Benefits Beyond Brain Protection
Which Vaccine Should You Get, and Does It Matter?
Outstanding Questions and What Researchers Don’t Yet Know
What This Means for Dementia Prevention Strategy
The Road Ahead—Toward Confirmation and Broader Application
Conclusion

How Can a Vaccine Against Shingles Lower Alzheimer’s and Dementia Risk?

The connection between shingles and dementia may seem counterintuitive, but researchers have developed a plausible biological explanation. The herpes zoster virus—the same virus that causes chickenpox in childhood and reactivates as shingles in adulthood—can trigger chronic inflammation and immune activation in the nervous system. This persistent inflammatory state has long been suspected as a contributing factor to cognitive decline and neurodegeneration. By preventing the shingles infection altogether with vaccination, the theory goes, you prevent the inflammatory cascade that might otherwise accelerate brain aging and amyloid accumulation, hallmarks of Alzheimer’s disease. The Wales study, which compared vaccination rates and dementia diagnoses across different age groups and communities, provided a natural experiment that largely sidesteps the bias problems that plague observational health research.

Researchers looked at groups with similar demographics, lifestyles, and healthcare access, then compared outcomes based on vaccination status. Among the 65-plus population vaccinated with two doses of the recombinant vaccine, the 51% risk reduction emerged as a robust finding, suggesting this isn’t merely correlation but reflects a real biological protective mechanism. It’s important to note that while this reduction is substantial, researchers haven’t yet established absolute causality. The mechanism remains partly theoretical, and confirmatory randomized controlled trials are now underway to determine whether giving the vaccine actually prevents dementia development, rather than simply identifying people less likely to develop dementia in the first place. This distinction matters because if the relationship is causal, it opens therapeutic avenues; if it’s merely correlational, the interpretation changes.

How Can a Vaccine Against Shingles Lower Alzheimer's and Dementia Risk?

The Real Impact on Dementia Progression and Mortality

Beyond prevention, the shingles vaccine appears to modify the course of dementia in those already diagnosed. Among people living with dementia who had been vaccinated, the mortality rate dropped significantly: from approximately 50% to 30% over nine years—a 29.5 percentage point reduction that translates into meaningful additional years of life. This suggests that vaccination doesn’t just prevent dementia from developing in healthy older adults; it seems to slow the disease’s destructive progression in those already affected. Another way to measure this protection is in days free from diagnosis. The recombinant vaccine provided an average of 164 additional days lived without a dementia diagnosis in those subsequently affected—representing a 17% increase in diagnosis-free time over six years post-vaccination.

To put this in practical terms: imagine a 70-year-old who receives the recombinant vaccine. If they later develop dementia, the vaccine may have delayed that diagnosis by roughly five months, a substantial window of preserved independence and cognitive function. However, it’s worth recognizing that this protection is not universal. Outcomes vary by vaccine type (the recombinant vaccine showed stronger effects than older live-attenuated vaccines), and research is still defining which populations benefit most. Women showed more pronounced protection than men in these studies, a difference that researchers are still working to explain but that highlights the importance of personalized medical assessment rather than one-size-fits-all recommendations.

Cardiovascular and Broader Health Benefits Beyond Brain Protection

The dementia risk reduction isn’t the only health benefit emerging from vaccination. The same inflammation that damages the brain also damages blood vessels and the heart. Vaccinated adults showed a 50% lower risk of vascular dementia—the type caused by reduced blood flow to the brain—as well as significant reductions in other cardiovascular events: 27% lower risk of blood clots, 25% lower risk of heart attack or stroke, and a 21% lower overall mortality risk over the study period. This constellation of benefits points to a broader anti-inflammatory effect of the shingles vaccine.

The virus doesn’t just inflame neural tissue; it activates immune responses throughout the body that contribute to atherosclerosis, clotting, and vascular dysfunction. By preventing herpes zoster infection, vaccination may be preventing a whole cascade of age-related inflammatory conditions. For many older adults, this expanded benefit profile strengthens the case for vaccination beyond dementia prevention alone. A practical example: A 72-year-old man with a family history of stroke and cognitive decline might choose to get vaccinated not just because of dementia prevention but because the 25% lower stroke risk and 27% lower clot risk also matter deeply to him. The vaccine becomes a multipurpose intervention, reducing several major causes of disability and death in one shot.

Cardiovascular and Broader Health Benefits Beyond Brain Protection

Which Vaccine Should You Get, and Does It Matter?

Not all shingles vaccines are equal when it comes to dementia protection. The recombinant zoster vaccine (Shingrix), approved in 2017, showed the most impressive dementia risk reduction of 51% in the 65-plus population when given as the recommended two-dose series. The older live-attenuated vaccine (Zostavax) provided some protection but less than the newer recombinant version. If you’re 50 or older and haven’t been vaccinated, or if you were vaccinated with the older vaccine before recombinant options became standard, discussing an update with your healthcare provider makes sense. The vaccination schedule also matters.

The study data strongly supports the two-dose regimen of the recombinant vaccine, given two to six months apart. A single dose provides some protection, but the full benefit appears to require both shots. This is worth keeping in mind if you’re considering vaccination; the dementia reduction data specifically backs the complete two-dose series, not partial vaccination. One practical consideration: getting vaccinated later rather than never still appears beneficial, though the evidence base is strongest for people who receive the vaccine before experiencing active shingles. If you’re 65 or older, or if you have risk factors for shingles or dementia, the evidence now supports vaccination regardless of age within that window. The only significant downside is the temporary arm soreness and possible mild flu-like symptoms that roughly one-third of vaccinees experience—hardly a serious trade-off against 51% dementia risk reduction.

Outstanding Questions and What Researchers Don’t Yet Know

While the findings are striking, major questions remain unanswered. The study compared groups across a real-world vaccination program but cannot yet prove causality—that’s why randomized controlled trials are now underway. If causality is confirmed, the mechanism will still need clarification. Does the vaccine prevent herpes zoster reactivation so completely that chronic inflammation simply doesn’t occur? Does the immune response trained by the vaccine somehow directly protect brain tissue? Or is there an indirect pathway through cardiovascular protection that secondarily protects cognition? These mechanistic questions matter because they might reveal whether the vaccine could work for people who can’t receive it for medical reasons, or whether similar benefits could come from other interventions targeting the same inflammatory pathway. Another limitation: the data comes from Wales, a relatively homogeneous population with strong healthcare records.

Whether these findings apply equally to diverse populations in the United States, Asia, and Africa remains to be determined. Early data suggests the protection may be somewhat stronger in women than men, but why that’s the case is unclear. Additionally, the long-term effects beyond nine years remain unknown. Does protection persist indefinitely, or does the benefit wane over decades? A cautionary note: while the vaccine showed remarkable dementia prevention benefits, it is not a silver bullet and should be understood as one part of a broader dementia prevention strategy. Maintaining cognitive reserve through education and mental stimulation, managing cardiovascular risk factors like blood pressure and cholesterol, staying physically active, managing sleep, and avoiding smoking and excessive alcohol all remain essential. The vaccine is an addition to these proven approaches, not a replacement for them.

Outstanding Questions and What Researchers Don't Yet Know

What This Means for Dementia Prevention Strategy

The shingles vaccine represents a significant addition to the dementia prevention toolkit, which has traditionally relied on lifestyle modifications and cardiovascular risk management. For older adults and caregivers looking for concrete preventive actions they can take, the vaccine offers something tangible and measurable. Unlike cognitive reserve, which takes years to build, or blood pressure control, which requires sustained medication adherence, vaccination is a simple two-shot series completed in months that appears to provide decades of protection.

Consider the case of a 63-year-old woman with a strong family history of Alzheimer’s disease, who is already exercising regularly and keeping her blood pressure controlled. Adding shingles vaccination to her prevention plan—before she reaches 65—gives her another protective tool with a 51% risk reduction. For someone at genetic risk, this additional layer of prevention can feel empowering and practical.

The Road Ahead—Toward Confirmation and Broader Application

The findings have already prompted major research institutions to launch randomized controlled trials to confirm whether the shingles vaccine actually causes dementia risk reduction or whether the association reflects other unmeasured factors. Results from these trials, expected within the next few years, will help establish whether vaccination should become a standard recommendation for dementia prevention.

If causality is confirmed, the public health implications are enormous—a relatively safe, widely available intervention that could prevent millions of cases of dementia globally. Looking forward, the findings also raise tantalizing questions about other infections and vaccines. Might other vaccines targeting chronic pathogens—such as herpes simplex, cytomegalovirus, or COVID-19 vaccines—also influence dementia risk through similar anti-inflammatory mechanisms? The answer will likely shape how we think about vaccination and brain health for decades to come.

Conclusion

Emerging evidence suggests that the shingles vaccine, already valuable for preventing a painful infection, may also significantly reduce the risk of Alzheimer’s disease and other dementias. With a 20% dementia risk reduction in the general population over 50 and a remarkable 51% reduction among those 65 and older who receive the two-dose recombinant vaccine series, the data warrants serious consideration for anyone in that age bracket. Even for those already living with dementia, vaccination appears to slow disease progression and extend survival, a dual benefit that extends the vaccine’s relevance across the lifespan.

If you’re 50 or older and haven’t been vaccinated against shingles, now is a logical time to discuss vaccination with your healthcare provider. The vaccine offers immediate protection against shingles itself, plus emerging evidence of brain health benefits and cardiovascular protection—a combination of benefits that few preventive interventions can match. As randomized trials confirm the mechanism over the coming years, what was already a sensible precaution may become recognized as a cornerstone of dementia prevention strategy.